Acadia Pharma EVP Schneyer sells $554k in stock

Acadia Pharmaceuticals (ACAD) reported strong Q2 2025 results, surpassing Wall Street's EPS and revenue forecasts with $0.16 and $264.6 million respectively, largely propelled by better-than-estimated Daybue sales. This positive financial performance prompted several analyst price target upgrades, including from Citizens JMP and Stifel, despite some varied initial reactions from Mizuho. Concurrently, the company's CFO executed a pre-planned sale of 22,000 shares valued at $554,023.

Analysis

Acadia Pharmaceuticals (ACAD) demonstrated strong operational performance in its second-quarter 2025 results, exceeding Wall Street expectations with an earnings per share of $0.16 against a $0.14 forecast and revenue of $264.6 million versus a $262.44 million projection. The revenue beat was primarily driven by outperformance from its drug Daybue, which generated $96.1 million in sales, surpassing estimates, while its established product Nuplazid met consensus with $168.5 million. This financial strength prompted positive analyst revisions, with Citizens JMP reiterating a Market Outperform rating and increasing its price target to $38, and Stifel raising its target to $24. However, analyst sentiment is not uniformly positive; Mizuho initially cut its target significantly before a modest post-earnings upward revision to $24, suggesting underlying concerns despite the solid results. Concurrently, the company's CFO sold 22,000 shares for approximately $554,023. This transaction's potential negative signal is substantially mitigated by the fact it was conducted under a Rule 10b5-1 trading plan adopted three months prior, and the executive retains a direct holding of 40,130 shares.

Key Decisions for Investors

• Investors should view the Q2 earnings beat, driven by Daybue's sales outperformance, and the subsequent price target upgrades from Stifel and Citizens JMP as evidence of solid commercial execution and a strengthening fundamental outlook.
• The CFO's share sale should be contextualized within the pre-arranged Rule 10b5-1 plan, which reduces the implication of negative insider sentiment, though the executive's remaining stake and future transactions warrant monitoring.
• Pay close attention to the varied analyst ratings, particularly the rationale behind Mizuho's initially cautious stance, as it may highlight risks or differing long-term views not immediately apparent from the headline earnings figures.